Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 9/2014

01-09-2014 | Review

Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease

Authors: Bradley A. Warady, Douglas M. Silverstein

Published in: Pediatric Nephrology | Issue 9/2014

Login to get access

Abstract

Anemia management is an important component of the care provided to children with chronic kidney disease (CKD) and influences both morbidity and mortality risk. The introduction of recombinant human erythropoietin to the treatment regimen three decades ago revolutionized the therapy and significantly decreased the need for repeated blood transfusions and exposure to associated risks. Recent data on the efficacy and complications associated with erythropoietic-stimulating agent (ESA) usage has, however, prompted a reassessment of treatment-related recommendations. This review will address these recommendations, in addition to describing pediatric outcomes associated with current ESAs and presenting information on alternative ESAs, many of which will likely soon be incorporated into clinical practice.
Literature
1.
Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality (2005) 2005 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Baltimore, Maryland
2.
Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, Martz K, Greenbaum LA (2008) Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 4:48–56PubMed
3.
Atkinson MA, Martz K, Warady BA, Neu AM (2010) Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 25:1699–1706PubMed
4.
Wong H, Mylrea K, Feber J, Drukker A, Filler G (2006) Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 70:585–590PubMed
5.
McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW (1984) Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25:437–444PubMed
6.
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316:73–78PubMed
7.
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int 2:279–335
8.
National Kidney Foundation (2006) K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47:S1–S146
9.
10.
Nangaku M, Eckardt KU (2006) Pathogenesis of renal anemia. Semin Nephrol 26:261–268PubMed
11.
Atkinson MA, Furth SL (2011) Anemia in children with chronic kidney disease. Nat Rev Nephrol 7:635–641PubMed
12.
Atkinson MA, Pierce CB, Zack RM, Barletta GM, Yadin O, Mentser M, Warady BA, Furth SL (2010) Hemoglobin differences by race in children with CKD. Am J Kidney Dis 55:1009–1017PubMedCentralPubMed
13.
Donnelly S (2001) Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 38:415–425PubMed
14.
Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, Yamamura K-I, Nagoshi N, Shibata S, Rao TN, Fehling HJ, Fukatsu A, Minegishi N, Kita T, Kimura T, Okano H, Yamamoto M, Yanagita M (2011) Dysfunction of fibroblasta of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 121:3981–3990PubMedCentralPubMed
15.
Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2006) Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr 149:671–675PubMed
16.
Mitsnefes M, Flynn J, Cole S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B, CKiD Study Group (2010) Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 21:137–144PubMedCentralPubMed
17.
Schaefer F (2008) Cardiac disease in children with mild-to moderate chronic kidney disease. Curr Opin Nephrol Hypertens 17:292–297PubMed
18.
Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N, Fivush B, Furth S (2004) Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44:1017–1023PubMed
19.
Borzych-Buzalka D, Bilginer Y, Ha IS, Bak M, Rees L, Cano F, Munarriz RL, Chua A, Pesle S, Emre S, Urzykowska A, Quiroz L, Ruscasso JD, White C, Pape L, Ramela V, Printza N, Vogel A, Kuzmanovska D, Simkova E, Muller-Wiefel DE, Sander A, Warady BA, Schaefer F, International Pediatric Peritoneal Dialysis Network (IPPN) Registry (2013) Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 24:665–676
20.
Furth SL, Cole SR, Fadrowski JJ, Gerson A, Pierce CB, Chandra M, Weiss R, Kaskel F, Council of Pediatric Nephrology and Urology, New York/New Jersey; Kidney and Urology Foundation of America (2007) The association of anemia and hypoalbuminemia with accelerated decline in GFR among adolescents with chronic kidney disease. Pediatr Nephrol 22:265–271PubMed
21.
Wuhl E, Schaefer F (2008) Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol 23:705–716PubMedCentralPubMed
22.
Filler G, Mylrea K, Feber J, Wong H (2007) How to define anemia in children with chronic kidney disease? Pediatr Nephrol 22:702–707PubMed
23.
Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S (2006) Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 17:2878–2885PubMed
24.
Warady BA, Ho M (2003) Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 18:1055–1062PubMed
25.
Maxwell PH, Ferguson DJ, Nicholls LG, Iredale JP, Pugh CW, Johnson MH, Ratcliffe PJ (1997) Sites of erythropoietin production. Kidney Int 51:393–401PubMed
26.
Nangaku M, Eckardt KU (2007) Hypoxia and the HIF system in kidney disease. J Mol Med (Berl) 85:1325–1330
27.
Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL (1996) Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88:1576–1582PubMed
28.
Pregi N, Wenker S, Vittori D, Leiros CP, Nesse A (2009) TNF-alpha-induced apoptosis is prevented by erythropoietin treatment on SH-SY5Y cells. Exp Cell Res 315:419–431PubMed
29.
Yang B, Hosgood SA, Bagul A, Waller HL, Nicholson ML (2011) Erythropoietin regulates apoptosis inflammation and tissue remodelling via caspase-3 and IL-1ß in isolated hemoperfused kidneys. Eur J Pharmacol 660:420–430PubMed
30.
Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, Badrawi SM, Lai P, Goldwasser E (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82:7580–7584PubMedCentralPubMed
31.
Sikole A, Spasovski G, Zafirov D, Polenakovic M (2002) Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol 57:237–245PubMed
32.
Spinowitz BS, Pratt RD, Epoetin Delta 2002 Study Group (2006) Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 22:25072513
33.
United States Renal Data System (2009) USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, 2009 (available at http://​www.​usrds.​org/​atlas09.​aspx)
34.
35.
Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290–299PubMed
36.
Egrie JC, Browne JK (2001) Development and characterisation of novel erythropoiesis-stimulating protein (NESP). Nephrol Dial Transplant 16(Suppl 3):3–13PubMed
37.
Debeljak N, Sytkowski AJ (2012) Erythropoietin and erythropoiesis-stimulating agents. Drug Test Anal 4:805–812PubMed
38.
Warady BA, Arar MY, Lerner G, Nakanishi AM, Stehman-Breen C (2006) Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatr Nephrol 21:1144–1152PubMed
39.
De Palo T, Giordano M, Palumbo F, Bellantuono R, Messina G, Colella V, Caringella AD (2004) Clinical experience with darbepoetin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 19:337–340PubMed
40.
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590PubMed
41.
Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084PubMed
42.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098PubMed
43.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMed
44.
Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL (2013) Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 61:44–56PubMedCentralPubMed
45.
Kliger AS, Fishbane S, Finkelstein FO (2012) Erythropoietic-stimulating agents and quality of a patient’s life: individualizing anemia treatment. Clin J Am Soc Nephrol 7:354–357PubMed
46.
Keithi-Reddy SR, Singh AK (2009) Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol 24:431–434PubMed
47.
48.
Foley RN (2008) Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev 13:405–414PubMed
49.
Port RE, Mehls O (2009) Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit? Pediatr Nephrol 24:435–437PubMed
50.
Port RE, Kiepe D, Van Guilder M, Jelliffe RW, Mehls O (2004) Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage. Clin Pharmacokinet 43:57–70PubMed
51.
Morris KP, Sharp J, Watson S, Coulthard MG (1993) Non-cardiac benefits of human recombinant erythropoietin in end-stage renal failure and anaemia. Arch Dis Child 69:580–586PubMedCentralPubMed
52.
Jabs K (1996) The effects of recombinant human erythropoietin on growth and nutritional status. Pediatr Nephrol 10:324–327PubMed
53.
Van Damme-Lombaerts R, Broyer M, Businger J, Baldauf C, Stocker H (1994) A study of recombinant human erythropoietin in the treatment of anemia of chronic renal failure in children on hemodialysis. Pediatr Nephrol 8:338–342PubMed
54.
Yalcinkaya F, Tumer N, Cakar N, Ozkaya N (1997) Low-dose erythropoietin is effective and safe in children on continuous ambulatory peritoneal dialysis. Pediatr Nephrol 11:350–352PubMed
55.
Gagnadoux MF, Loirat C, Berthélémé JP, Maisin A, Kamoun A, Dabout D, Poisson D, Broyer M (1994) Treatment of anemia in hemodialyzed children using recombinant human erythropoietin (Eprex). Results of a French multicenter clinical trial. Nephrologie 15:207–211PubMed
56.
Chavers BM, Roberts TL, Herzog CA, Collins AJ, St Peter WL (2004) Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int 65:266–273PubMed
57.
van Stralen KJ, Krischock L, Schaefer F, Verrina E, Groothoff JW, Evans J, Heaf J, Ivanov D, Kostic M, Maringhini S, Podracka L, Printza N, Pundziene B, Reusz GS, Vondrak K, Jager KJ, Tizard EJ, ESPN/ERA-EDTA Registry (2012) Prevalence and predictors of the sub-target Hb level in children on dialysis. Nephrol Dial Transplant 27:3950–3957PubMed
58.
Opelz G, Graver B, Mickey MR, Terasaki PI (1981) Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation 32:177–183PubMed
59.
Opelz G, Vanrenterghem Y, Kirste G, Gray DW, Horsburgh T, Lachance JG, Largiader F, Lange H, Vujaklija-Stipanovic K, Alvarez-Grande J, Schott W, Hoyer J, Schnuelle P, Descoeudres C, Ruder H, Wujciak T, Schwarz V (1997) Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 63:964–967PubMed
60.
Sinai-Trieman L, Salusky IB, Fine RN (1989) Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr 114:550–554PubMed
61.
Kokot F, Wiecek A, Grzeszczak W (1991) Decreased need for blood transfusion during one year after discontinued erythropoietin treatment in haemodialyzed patients. Nephron 58:246–247PubMed
62.
Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Fine RN, Ettenger RB (1990) Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38:12–18PubMed
63.
Berland Y, Baz M, Di Stefano D, Merzouk T, Bartoli JM, Dussol B, Kasbarian M (1992) Recombinant human erythropoietin treatment reverses hepatic iron overload in hemodialysis patients. Nephrol Dial Transplant 7:366–367PubMed
64.
Warady BA, Sabath RJ, Smith CA, Alon U, Hellerstein S (1991) Recombinant human erythropoietin in pediatric patients receiving long-term peritoneal dialysis. Pediatr Nephrol 5:718–723PubMed
65.
Burke JR (1995) Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Australian and New Zealand Paediatric Nephrology Association. Pediatr Nephrol 9:558–561PubMed
66.
Montini G, Zacchello G, Baraldi E, Zanconato S, Suppiej A, Fabris F, Andreetta B, Pavanello L, Zacchello F (1990) Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. J Pediatr 117:556–560PubMed
67.
Bamgbola OF (2011) Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int 80:464–474PubMed
68.
Kalantar-Zadeh K, Höffken B, Wünsch H, Fink H, Kleiner M, Luft FC (1995) Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26:292–299PubMed
69.
Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, Dahl NV, Watkins SL (2004) Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 19:655–661PubMed
70.
Warady BA, Zobrist RH, Wu J, Finan E, Ferrlecit Pediatric Study Group (2005) Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 20:1320–1327PubMed
71.
Goldstein S, Morris D, Warady BA (2013) Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial. Am J Kidney Dis 61:588–597PubMed
72.
Young B, Zaritsky J (2009) Hepcidin for clinicians. Clin J Am Soc Nephrol 4:1384–1387PubMed
73.
Atkinson MA, White CT (2012) Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 27:33–40PubMed
74.
Bamgbola O (2012) Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations. Pediatr Nephrol 27:195–205PubMed
75.
Macdougall I, Cooper A (2002) Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17:S39–S43
76.
Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, Kovesdy CP, Kalantar-Zedeh K (2012) Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. doi:10.​1093/​ndt/​gfs368 PubMedCentralPubMed
77.
Gallieni M, Corsi C, Brancaccio D (2000) Hyperparathyroidism and anemia in renal failure. Am J Nephrol 20:89–96PubMed
78.
Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB (2006) Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialyzed patients? Nephrology 11:394–399PubMed
79.
Bamgbola OF, Kaskel F (2005) Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr Nephrol 20:1622–1629PubMed
80.
Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Eng J Med 346:469–475
81.
Macdougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Hörl WH, Kemeny DM, Pollock C (2012) Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int 81:727–732PubMed
82.
Mattison P, Upadhyay K, Wilcox JE, Moudgil A, Silverstein DM (2010) Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient. Pediatr Nephrol 25:971–976PubMed
83.
Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, Forrest DL, Gagnon RF, Harvey EA, Laneuville P, Patterson BJ, Poon MC, Posen GA, Messner HA, Canadian PRCA Focus Group (2004) Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 15:2728–2734PubMed
84.
Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y (2011) Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol 126:114–118PubMed
85.
Verhelst D, Rossert J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC (2004) Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 363:1768–1771PubMed
86.
Andrade J, Taylor PA, Love JM, Levin A (2005) Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. Nephrol Dial Transplant 20:2548–2551PubMed
87.
Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU (2009) A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 361:1848–1855PubMed
88.
Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF (2010) Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153:23–33PubMed
89.
Brandt JR, Avner ED, Hickman RO, Watkins SL (1999) Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol 13:143–147PubMed
90.
Coyne DW (2012) The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 82:235–241PubMedCentralPubMed
91.
Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK (2011) Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 22:358–365PubMedCentralPubMed
92.
Chaknos CM, Berns JS (2013) Erythropoiesis-stimulating agents on trial: are higher dosages causing harm? Am J Kidney Dis 61:6–8PubMed
93.
Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538–548PubMed
94.
Vaziri ND, Zhou XJ (2009) Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 24:1082–1088PubMed
95.
Morakkabati N, Gollnick F, Meyer R, Fandrey J, Jelkmann W (1997) Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol 24:392–397
96.
Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazão JM, Goldsmith D, Ronco P, Spasovski GB, Stenvinkel P, Utas C, Wiecek A, Zoccali C, London G (2011) Biosimilars and biopharmaceuticals: what nephrologists need to know—a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 23:3731–3737
97.
Jelkmann W (2012) Biosimilar recombinant human erythropoietins (“epoetins”) and future erythropoiesis-stimulating treatments. Expert Opin Biol Ther 12:581–592PubMed
98.
Wish JB (2011) Erythropoiesis-stimulating agents and pure red-cell aplasia: you can’t fool Mother Nature. Kidney Int 80:11–13PubMed
99.
Ahmed I (2011) Biosimilars in the US - Guidance from the European Experience. US Nephrol 6:84–90
100.
Macdougall IC (2012) New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 59:444–451PubMed
101.
Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, Teerapornlertratt T, Lumlertkul D, Townamchai N, Susantitaphong P, Katavetin P, Kanjanabuch T, Avihingsanon Y, Eiam-Ong S (2011) Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 80:88–92PubMed
102.
Macdougall IC, Ashenden M (2009) Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chron Kidney Dis 16:117–130
103.
Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273:458–464PubMed
104.
Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW (2006) Preclinical evaluation of hematide, a novel erythropoiesis-stimulating agent, for the treatment of anemia. Exp Hematol 34:1303–1311PubMed
105.
Del Vecchio L, Locatelli F (2011) New treatment approaches in chronic kidney disease-associated anemia. US Nephrol 6:91–94
106.
Macdougall IC, Wiecek A, Tucker B, Yaqoob M, Mikhail A, Nowicki M, MacPhee I, Mysliwiec M, Smolenski O, Sułowicz W, Mayo M, Francisco C, Polu KR, Schatz PJ, Duliege AM (2011) Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol 6:2579–2586PubMedCentralPubMed
107.
Locatelli F, Vecchio L (2011) New erythropoiesis-stimulating agents and new iron formulations. In: Ronco C, Rosner M (eds) Hemodialysis: New methods and future technology. Karger, Basel, pp 255–260
108.
Fishbane S, Roger SD, Martin E, Runyan G, O’Neil J, Qiu P, Locatelli F (2012) Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. Clin J Am Soc Nephrol 8:538–545PubMedCentralPubMed
109.
Pérez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, Miller B, Jang H, Bai SA, Zhou H, Yohrling J, Cohen A, Burggraaf J, Franson K, Davis HM (2009) Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. Clin Pharmacokinet 48:601–613PubMed
110.
Locatelli F, Villa G, de Francisco AL, Albertazzi A, Adrogue HJ, Dougherty FC, Beyer U, BA 16286 Study Investigators (2007) Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 23:969–979PubMed
111.
Cano F, Alarcon C, Azocar M, Lizama C, Maria Lillo A, Delucchi A, Gonzalez M, Arellano P, Delgado I, Droguett MT (2011) Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol 26:1303–1310PubMed
112.
Beuck S, Schanzer W, Thevis M (2012) Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal 4:830–845PubMed
113.
Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, Eckardt KU (2010) Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21:2151–2156PubMedCentralPubMed
114.
Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447–5454PubMedCentralPubMed
115.
Brill-Almon E, Stern B, Afik D, Kaye J, Langer N, Bellomo S, Shavit M, Pearlman A, Lippin Y, Panet A, Shani N (2005) Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins. Mol Ther 12:274–282PubMed
116.
Wang G, Liu LN, Lee K, Buyaner D, Hendricks K, Kalfoglou CS, Bohnlein E, Junker U, Mosca JD (2009) Comparison of drug and cell-based delivery-engineering adult mesenchymal stem cells to deliver human erythropoietin. Gene Ther Mol Biol 13:321–330
117.
Joung CH, Shin JY, Koo JK, Lim JJ, Wang JS, Lee SJ, Tan HK, Kim SL, Lim SM (2009) Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell. Protein Expr Purif 68:137–145PubMed
118.
Schriebl K, Trummer E, Lattenmayer C, Weik R, Kunert R, Müller D, Katinger H, Vorauer-Uhl K (2006) Biochemical characterization of rhEPO-Fc fusion protein expressed in CHO cells. Protein Expr Purif 49:265–275PubMed
119.
Ingley E, Tilbrook PA, Klinken SP (2004) New insights into the regulation of erythroid cells. IUBMB Life 56:177–184PubMed
120.
Nakano Y, Imagawa S, Matsumoto K, Stockmann C, Obara N, Suzuki N, Doi T, Kodama T, Takahashi S, Nagasawa T, Yamamoto M (2004) Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 104:4300–4351PubMed
121.
Angelillo-Scherrer A, Burnier L, Lambrechts D, Fish RJ, Tjwa M, Plaisance S, Sugamele R, DeMol M, Martinez-Soria E, Maxwell PH, Lemke G, Goff SP, Matsushima GK, Earp HS, Chanson M, Collen D, Izui S, Schapira M, Conway EM, Carmeliet P (2008) Role of Gas6 in erythropoiesis and anemia in mice. J Clin Invest 118:583–596PubMedCentralPubMed
122.
Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G (2010) Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 115:3616–3624PubMed
123.
Spaninger K, Debeljak N (2009) Erythropoietin, epoetins and detection. Pharm J Slov 60:279
124.
Akebia Therapeutics Inc (2011) Akebia announces positive results for AKB-6548 phase 1 clinical study. Ref Type: Internet Communication
125.
Bayer Healthcare (2011) Single dose group stratified study in renal impaired and healthy aged and gender matched subjects. Ref Type: Internet Communication
Metadata
Title
Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease
Authors
Bradley A. Warady
Douglas M. Silverstein
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 9/2014
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-013-2557-x

Other articles of this Issue 9/2014

Pediatric Nephrology 9/2014 Go to the issue

Brief Report

Painful micturition in a small child: an unusual clinical picture of paroxysmal extreme pain disorder

Original Article

Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis

Original Article

Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome

Original Article

Extended-spectrum β-lactamase-producing bacteria causing community-acquired urinary tract infections in children

Original Article

Natural history of genetically proven autosomal recessive Alport syndrome

Educational Review

Malignancies after pediatric kidney transplantation: more than PTLD?